N/a Tablet, Film Coated
Product Images NDC 35561-255

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for N/a (NDC 35561-255). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bostal Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg-30 (10mg 30)

This is a description of Tadalafil Tablets, USP with a dosage of 10 mg. The instructions indicate that the entire dose should be taken and the tablets should not be split. The package contains 30 tablets and is for prescription use only.*

FDA Label Image

10mg-500 (10mg 500)

This text is a pharmaceutical label for Tadalafil Tablets, with a concentration of 10 mg per tablet. It is indicated that the tablets should not be split, and the entire dose should be taken. The label includes product information such as the manufacturer (AustarPharma) and the quantity of tablets provided (500 tablets). The text also contains a National Drug Code (NDC) for the product.*

FDA Label Image

2-5mg-30 (2 5mg 30)

This is a product label for Tadalafil Tablets, USP 25 mg. The tablets should not be split, and the entire dose should be taken. This is a prescription medication with 30 tablets per package.*

FDA Label Image

2-5mg-500 (2 5mg 500)

This text provides details about a pharmaceutical product with NDC 35561-254-13 as the identifier for 500 tablets. The text includes product information along with some numeric data but does not provide a comprehensive description.*

FDA Label Image

20mg-30 (20mg 30)

This text includes details about Tadalafil Tablets, USP with a dosage indication that the tablets should not be split and the entire dose should be taken. It also mentions that the product comes in a pack of 30 tablets and provides the National Drug Code (NDC) 35561-257-10. This information is intended for prescription use only.*

FDA Label Image

20mg-500 (20mg 500)

This is a description of Tadalafil Tablets, USP, which are prescription-only medications. The tablets should not be split, and the entire dose should be taken as directed. Each tablet contains 6.0000".*

FDA Label Image

5mg-30 (5mg 30)

This is a description for Tadalafil Tablets. These tablets should not be split, and the entire dose should be taken. The package contains 30 tablets. The product is for prescription use only.*

FDA Label Image

5mg-500 (5mg 500)

This text appears to be a label or description for Tadalafil tablets with a prescription use. It specifies that the tablets should not be split and the entire dose should be taken. The information also includes a National Drug Code (NDC) as 35561-255-13 and mentions the quantity as 500 tablets.*

FDA Label Image

Figure1 (Figure1)

This text presents a figure showing the mean maximal change in blood pressure (specifically Systolic and Diastolic) when Tadalafil is compared to a placebo in response to Sublingual Nitroglycerin at different time intervals after the last dose of Tadalafil 20 mg or Placebo. The measurements include Standing Systolic and Diastolic BP, Supine Systolic and Diastolic BP, with time intervals at 2, 4, 8, 24, 48, 72, and 96 hours.*

FDA Label Image

Figure2 (Figure2)

This is a medical evaluation of a study comparing the effect of Tadalafil 20 mg & Doxazosin 8 mg versus Placebo & Doxazosin 8 mg on systolic blood pressure. The study evaluates the mean change from baseline in systolic blood pressure over time post-dose. The results are displayed graphically in Figure 2.*

FDA Label Image

Figure3 (Figure3)

This text provides information on a study involving the administration of different doses of tadalafil and doxazosin at different times. The study evaluates the mean change in systolic blood pressure over time. The results are presented graphically in Figure 3 as part of a study on doxazosin.*

FDA Label Image

Figure4 (Figure4)

This medical chart shows the plasma tadalafil concentrations following different doses, including a single 20-mg dose, a single 5-mg dose, and a once-daily 5-mg dose over five consecutive days. The graph displays the mean concentration with standard deviation over time (hours). This information is helpful for understanding tadalafil pharmacokinetics and dosage effects.*

FDA Label Image

Figure5 (Figure5)

This text provides information about a study comparing Tadalafil 5mg with Placebo in BPH (Benign Prostatic Hyperplasia) patients over a duration of 12 weeks. It shows mean IPSS (International Prostate Symptom Score) changes at different visits. Tadalafil is a medication used to treat erectile dysfunction and symptoms of enlarged prostate. The figure displayed likely presents the effectiveness of Tadalafil in improving symptoms in BPH patients compared to a placebo.*

FDA Label Image

Figure6 (Figure6)

This text provides information on the comparison of Tadalafil 5 mg and Placebo in BPH patients over weeks of treatment. The figure shows the Mean IPSS Changes by visit in Study K, illustrating the effectiveness of Tadalafil in managing symptoms related to BPH.*

FDA Label Image

Figure7 (Figure7)

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.